https://parvustx.com/news-media/ 2026-10-19T15:09:40+00:00 https://parvustx.com/parvus-announces-first-human-subject-dosed-in-a-clinical-trial-evaluating-pvt201-a-first-in-class-off-the-shelf-regulatory-t-cell-treg-inducing-pmhc-nanomedicine-therapy/ 2026-03-20T12:55:13+00:00 https://parvustx.com/parvus-announces-achievement-of-first-milestone-from-its-collaboration-agreement-with-abbvie-to-develop-ibd-therapies-based-on-the-parvus-nanomedicine-platform-technology/ 2026-03-20T12:55:13+00:00 https://parvustx.com/parvus-therapeutics-reports-positive-phase-1-results-for-lead-autoimmune-treg-therapy-pvt201/ 2026-03-20T12:55:13+00:00 https://parvustx.com/parvus-therapeutics-announces-exclusive-worldwide-license-and-collaboration-agreement-for-the-development-and-commercialization-of-its-lead-nanomedicine-to-treat-type-1-diabetes/ 2026-03-20T12:55:14+00:00 https://parvustx.com/parvus-therapeutics-nanotechnology-treatment-reprograms-immune-cells-to-reverse-autoimmune-disease-as-published-in-nature/ 2026-03-20T12:55:14+00:00 https://parvustx.com/parvus-therapeutics-announces-key-executive-and-board-of-directors-appointments/ 2026-03-20T12:55:14+00:00 https://parvustx.com/parvus-therapeutics-publication-of-preclinical-proof-of-concept-research-that-underlies-the-development-of-navacim-therapeutics-for-the-treatment-of-autoimmune-liver-diseases/ 2026-03-20T12:55:14+00:00 https://parvustx.com/parvus-therapeutics-announces-ceo-senior-executive-and-board-of-directors-appointments/ 2026-03-20T12:55:14+00:00 https://parvustx.com/913-2/ 2026-03-20T12:55:14+00:00 https://parvustx.com/parvus-therapeutics-and-ardena-enter-agreement-for-tech-transfer-scale-up-and-gmp-manufacturing-of-navacim-nanoparticles/ 2026-03-20T12:55:14+00:00 https://parvustx.com/parvus-therapeutics-announces-development-and-manufacturing-agreement-with-resilience-to-advance-novel-autoimmune-drug-candidate-pvt201/ 2026-03-20T12:55:14+00:00 https://parvustx.com/parvus-therapeutics-announces-a-publication-describing-the-cellular-origin-of-treg-cells-generated-endogenously-by-navacim-therapy/ 2026-03-20T12:55:14+00:00 https://parvustx.com/parvus-announces-collaboration-with-abbvie-to-develop-ibd-therapies-based-on-the-parvus-navacim-platform-technology/ 2026-03-20T12:55:14+00:00 https://parvustx.com/parvus-therapeutics-announces-that-pvt201-has-received-orphan-drug-designation/ 2026-03-20T12:55:14+00:00 https://parvustx.com/parvus-therapeutics-announces-leadership-appointments-to-support-development-from-preclinical-into-clinical/ 2026-03-20T12:55:14+00:00 https://parvustx.com/parvus-therapeutics-initiates-first-in-human-clinical-trial-of-pvt401-for-inflammatory-bowel-disease/ 2026-05-01T19:42:56+00:00 https://parvustx.com/parvus-therapeutics-announces-fda-clearance-of-investigational-new-drug-application-for-pvt201/ 2026-10-19T15:09:40+00:00